In a major move to expand its international footprint, Indian pharmaceutical giant Zydus Lifesciences has announced the acquisition of U.S.-based Assertio Holdings. The deal, valued at approximately $166.4 million—roughly 1,570 crore rupees—is a strategic step to solidify Zydus’ presence in the world’s largest healthcare market.
The acquisition will be executed through Zydus’ subsidiary, Zydus Worldwide DMCC, and its vehicle, Zara Merger Sub Inc. Under the terms of the all-cash agreement, Zydus will offer $23.50 per share. This bid represents a significant premium over previous offers from Garda Therapeutics, which Assertio’s board recently abandoned in favor of Zydus’ superior value and execution certainty.
Through this acquisition, Zydus gains a ready-made commercial platform in the United States. Assertio specializes in branded prescription products, with a heavy focus on pain management and oncology support. A key asset in this deal is Rolvedon, an FDA-approved long-acting biologic used to reduce infection risks in cancer patients undergoing chemotherapy.
Zydus Lifesciences Managing Director, Sharvil Patel, emphasized that the transaction is pivotal for building a “differentiated and durable” specialty business globally. By leveraging Assertio’s established marketing and distribution networks, Zydus aims to accelerate its growth in the high-margin specialty oncology sector.
The transaction is structured as a tender offer followed by a merger. It is expected to be finalized in the 2027 fiscal year, pending customary closing conditions and the tender of a majority of outstanding shares. Once the deal is complete, Assertio will be delisted from the Nasdaq, marking a new chapter for Zydus’ American operations.
